Teaming Up to Tackle HIV

Evergreen Health and UB Department of Medicine Participating in Clinical Trial investigating long-acting injectable treatment for HIV

Only location in Upstate New York

Evergreen Health and the University at Buffalo Department of Medicine – HIV and Infectious Diseases are participating in a multicenter clinical trial investigating the safety and efficacy of a regimen to treat HIV that is administered in monthly injections. ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, is sponsoring the trial. The first investigational long-acting injections are scheduled during May.  The injections will be administered at Evergreen Health.

“I am honored to have been selected to participate in this trial,” said Dr. Alyssa Shon, Principal Investigator of the Trial and Medical Director, Evergreen Health (pictured on left). Adherence is key to successful HIV therapy, and medication regimens that do not require daily dosing could transform how we treat HIV infection.”

The Antiretroviral Therapy as Long Acting Suppression (ATLAS) study is a global phase III study with a two-drug investigational regimen of long-acting, injectable cabotegravir (ViiV Healthcare) and long-acting injectable rilpivirine (Janssen Pharmaceuticals) in virally suppressed adults living with HIV. This injectable drug therapy, which is administered every four weeks, differs from most current antiretroviral drug therapy that is taken orally on a daily basis.

The University at Buffalo Department of Medicine – HIV and Infectious Diseases Division has been actively involved in HIV clinical trials for more than three decades. This clinical trial is another way that Evergreen and the University at Buffalo continue to collaborate to enhance HIV care in our region.

 

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s